Just In
- 15 hrs ago Heeramandi Screening: Alia Bhatt, Ananya Panday, Rashmika Mandanna And Others Serve Finest Ethnic Style!
- 16 hrs ago From Alia Bhatt To Kriti Sanon, Korean Beauty Products That Bollywood Divas Swear By
- 19 hrs ago Exclusive: On World Malaria Day 2024, Dr Shares Danger Signs Parents Must Watch Out For In Child With Malaria
- 19 hrs ago Exclusive: Expert Debunks 5 Common Misconceptions About Expectant Mothers That You Need To Steer Clear From
Don't Miss
- Movies Pavi Caretaker Box Office Collection Day 1 Prediction: Dileep's Movie Expected To Open Strongly
- Sports Who Won Yesterday's IPL Match 41? SRH vs RCB, IPL 2024 on April 25: Royal Challengers Bangalore End Losing Streak
- Finance Bajaj Group Stock Declares Rs. 60/Share Dividend: Buy Ahead of Record Date On 28 June?
- News MEA Dismisses US Human Rights Report On Manipur As 'Biased And Misinformed'
- Automobiles Royal Enfield Unveils Revolutionary Rentals & Tours Service: Check Out All Details Here
- Technology Elon Musk’s X Is Launching a TV App Similar to YouTube for Watching Videos
- Education AICTE introduces career portal for 3 million students, offering fully-sponsored trip to Silicon Valley
- Travel Escape to Kalimpong, Gangtok, and Darjeeling with IRCTC's Tour Package; Check Itinerary
Covaxin Gets WHO Approval For Emergency Use Listing
The Technical Advisory Group (TAG), an independent advisory committee of the World Health Organisation (WHO), has recommended Emergency Use Listing (EUL) status for Bharat Biotech COVID-19 vaccine Covaxin, sources in the know of the development said. The WHO is in the process of evaluating Covaxin's clinical trial data for use of EUL. The TAG on October 26 had sought "additional clarifications" from the company for Covaxin to conduct a final "risk-benefit assessment" for Emergency Use Listing of the vaccine.
"The Technical Advisory Group of WHO has recommended Emergency Use Listing status for Covaxin," a source told PTI. The TAG-EUL is an independent advisory group that provides recommendations to WHO on whether a COVID-19 vaccine can be listed for emergency use under the EUL procedure. Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant. In June, the company said it concluded the final analysis of Covaxin efficacy from Phase 3 trials.
Hyderabad-based Bharat Biotech had submitted EOI (Expression of Interest) to the World Health Organisation on April 19 for the vaccine's Emergency Use Listing (EUL).
India's Bharat Biotech has been submitting data on the EUL of Covaxin regularly and very quickly to a technical committee which hopes to have a final recommendation to the WHO next week, a top official of the global health agency said on Thursday, stressing that the UN body "trusts" the Indian industry that manufactures high-quality vaccines.
What Is Toddler Acne? Causes, Symptoms, Complications, Diagnosis And Treatments
The WHO has so far approved Covid-19 vaccines of Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India, Johnson & Johnson-Janssen, Moderna, and Sinopharm for emergency use.
Bharat Biotech on Wednesday also issued a statement saying that the Central Drugs Standard Control Organisation (CDSCO) has approved the extension of the shelf life of its COVID-19 vaccine Covaxin up to 12 months from the date of manufacture. This move will help hospitals, especially private hospitals, use up their stock of the vaccine.
"The CDSCO has approved the extension of shelf life of Covaxin up to 12 months, from the date of manufacture. This approval of shelf-life extension is based on the availability of additional stability data, which was submitted to CDSCO," Bharat Biotech said in a tweet.
The shelf life extension has been communicated to "our stakeholders," it added.
- healthCOVID-19 Vaccines and Heart Attacks: New Studies Show Different Results; What Are They?
- wellnessCorbevax Will Be Allowed As A Booster For Those Fully Vaccinated With Covishield Or Covaxin
- kidsCovid-19 Vaccines For Kids: DCGI Grants Emergency Use Nod To 3 Vaccines For Different Age Group Of Children
- wellnessBooster Dose Of COVID Vaccine Needed To Fight Against Omicron: Study
- wellnessIndia's Covaxin To Be Evaluated As COVID-19 Vaccine Candidate In USA
- healthCovaxin Granted Emergency Use Listing In 13 Nations As On Jan 31 According To WHO: Government
- healthEach Dose Of Covishield, Covaxin Likely To Be Capped At Rs 275 After Getting Regular Market Approval
- healthMedia Reports Stating Vaccine Shortage In Maharashtra Are Not Factually Correct: Govt
- healthGovt's Decision On COVID-19 Vaccination For Children 'Unscientific': Senior AIIMS Epidemiologist
- healthCovaxin's Shelf Life Extended To 12 Months From Date Of Manufacture
- healthExperts Allay Covaxin Concerns, Say 50% Effectiveness Against Delta-Driven COVID-19 Surge Not Bad
- healthGovernment Nod To Commercial Export Of Covishield, Covaxin In View Of Sufficient Stock